Veeva Systems (NYSE:VEEV) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Veeva Systems (NYSE:VEEV) issued its quarterly earnings data on Wednesday. The technology company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13, FiscalAI reports. The company had revenue of $927.96 million for the quarter, compared to analysts’ expectations of $905.38 million. Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. Veeva Systems’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.99 earnings per share. Veeva Systems updated its FY 2027 guidance to 9.210-9.210 EPS and its Q3 2027 guidance to 2.330-2.340 EPS.

Here are the key takeaways from Veeva Systems’ conference call:

• Veeva reported a strong second quarter, with revenue of $928 million and non-GAAP operating income of $416 million, both ahead of guidance.
• Customer interest in Falcon’s AI-driven “agentic labor” is high, with five early adopters and initial go-lives expected this year; management said demand currently exceeds its ability to deliver the product.
• Commercial subscription revenue grew about 13% year over year, or double digits excluding Crossix, with broad-based strength across CRM, content, data, Crossix, and Ostro.
• Veeva highlighted strong CRM momentum, including two major top-20 biopharma wins and 12 of the top 20 customers committed to Vault CRM; management also sees potential to win back some customers encountering delays with Salesforce implementations.
• R&D growth is transitioning from established products such as eTMF, CTMS, and QualityDocs toward earlier-stage offerings including EDC, eCOA, RTSM, Safety, and LIMS, which management views as significant long-term opportunities but says have different adoption timelines.

Veeva Systems Price Performance

NYSE VEEV opened at $244.72 on Thursday. The business has a 50 day simple moving average of $203.41 and a 200 day simple moving average of $183.04. Veeva Systems has a one year low of $148.05 and a one year high of $310.50. The stock has a market capitalization of $39.75 billion, a P/E ratio of 43.62, a P/E/G ratio of 1.06 and a beta of 0.92.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Quarterly results exceeded expectations. Veeva reported fiscal Q2 revenue of $928.0 million, up 17.6% year over year, including subscription revenue of $766.8 million, up 16%. Earnings of $2.35 per share surpassed the $2.22 consensus estimate. Veeva Announces Fiscal 2027 Second Quarter Results
• Positive Sentiment: Forward guidance was materially above Wall Street forecasts. Veeva guided fiscal Q3 revenue to $932 million-$935 million and EPS to $2.33-$2.34, compared with consensus estimates of $917.9 million and $2.16, respectively. Fiscal 2027 revenue guidance was approximately $3.7 billion and EPS guidance was $9.21, both above analyst expectations.
• Positive Sentiment: AI and CRM momentum supported the outlook. Management expects the first customers to go live with Falcon, its next-generation AI offering, this year, while targeting retention of more than 70% share of the life sciences CRM market. Management also highlighted AI-driven demand and continued adoption of its Vault platform. Veeva CRM and Falcon Update
• Positive Sentiment: Major customer wins strengthened the competitive case. Regeneron and Biogen committed to Veeva Vault CRM globally, providing evidence that Veeva is maintaining its market leadership and expanding adoption among large biopharmaceutical companies. Veeva Vault CRM Selected by Regeneron
• Neutral Sentiment: Needham reaffirmed a Buy rating, while Piper Sandler initiated coverage. These analyst actions add support but are less significant than the earnings and guidance updates. Needham Reaffirms Buy Rating
• Neutral Sentiment: Veeva’s 28.37% net margin, strong balance-sheet profile, and recurring subscription model remain attractive, although the stock’s elevated valuation—with a reported P/E ratio above 43—leaves less room for execution disappointments.

Analysts Set New Price Targets

VEEV has been the subject of several recent research reports. Wall Street Zen cut Veeva Systems from a “buy” rating to a “hold” rating in a research note on Monday, August 3rd. Oppenheimer lifted their price objective on Veeva Systems from $225.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, August 17th. Citigroup upped their target price on Veeva Systems from $176.00 to $190.00 and gave the company a “neutral” rating in a report on Thursday, June 4th. Canaccord Genuity Group decreased their target price on shares of Veeva Systems from $235.00 to $220.00 and set a “hold” rating for the company in a research report on Thursday, June 4th. Finally, BNP Paribas Exane reissued an “outperform” rating and set a $285.00 target price on shares of Veeva Systems in a research report on Thursday, June 4th. Nineteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $258.08.

Insider Transactions at Veeva Systems

In other Veeva Systems news, insider Thomas D. Schwenger sold 36,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the transaction, the insider directly owned 19,449 shares in the company, valued at approximately $4,866,723.27. This represents a 64.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Williams Jones Wealth Management LLC. grew its holdings in shares of Veeva Systems by 0.4% during the third quarter. Williams Jones Wealth Management LLC. now owns 9,419 shares of the technology company’s stock worth $2,806,000 after purchasing an additional 40 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in Veeva Systems by 0.7% in the 2nd quarter. Rafferty Asset Management LLC now owns 6,881 shares of the technology company’s stock valued at $1,982,000 after buying an additional 51 shares during the last quarter. Brown Brothers Harriman & Co. boosted its position in Veeva Systems by 8.1% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 719 shares of the technology company’s stock worth $214,000 after buying an additional 54 shares during the period. Raiffeisen Bank International AG boosted its position in Veeva Systems by 59.8% during the 4th quarter. Raiffeisen Bank International AG now owns 155 shares of the technology company’s stock worth $35,000 after buying an additional 58 shares during the period. Finally, Rakuten Securities Inc. grew its holdings in Veeva Systems by 56.7% during the 2nd quarter. Rakuten Securities Inc. now owns 163 shares of the technology company’s stock worth $47,000 after acquiring an additional 59 shares during the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.